A pediatric patient with very early meningeal relapse of his CD34
Pediatric patients with high-risk of relapse of ALL are frequently treated with transplantation of allogeneic bone marrow (BM) or peripheral blood stem cells (PBSC). However, despite allogeneic transplantation, prognosis for patients with a very early meningeal relapse of leukemia remains poor. Few case reports suggest a better outcome in these patients after autologous transplantation. 1 It has been shown that clonogenic tumor cells within the graft can cause relapse of the disease. 2 To avoid relapse from reinfusion of grafts, CD34 selection of stem cells is a well-established strategy to remove contaminating tumor cells from autografts in CD34-negative solid tumors of pediatric patients. 3 To reach high purity of the stem cell transplant, refined selection strategies are needed. In order to eliminate potentially CD34-positive tumor cells from autologous grafts, we established a clinical scale CD133 selection procedure for pediatric patients with neuroblastoma. 4 CD133 is a novel stem cell glycoprotein antigen selectively expressed on CD34 bright progenitor cells. 5 Here, we report on the application of this new selection strategy for purification of an autologous graft and transplantation of a boy with relapsed CD34-positive CD133-negative ALL.
Patients and methods

Case report
An 11-year-old boy with a pre-B-ALL suffered very early isolated meningeal relapse. Initially, he had been treated with polychemotherapy according to ALL-BFM 95 (German/Austrian multicenter study) from July 1999 to February 2000. At that time, flow cytometric immunophenotyping of the leukemic blasts showed positivity for antigenes CD19, CD20, CD24, CD22, cyCD22, CD10, CD34, HLA-DR but negative for CD133. Moreover, the blasts were negative for the fusion transcripts TEL-AML1, BCR-ABL and MLL-1 as determined by PCR. Fourteen months later, isolated meningeal relapse was confirmed by magnetic resonance imaging and lumbar and bone marrow puncture. From October 2000, the boy was treated according to ALL-BFM-Rez 96 including intrathecal application of methotrexate, cytosine arabinoside and prednisolone and intravenous application of dexamethasone, methotrexate, vincristine and PEG-asparaginase. For the poor prognosis of both conventional chemotherapy and allogeneic transplantation in this case, we decided on high-dose chemotherapy and autologous transplantation.
Autologous stem cell harvesting
Autologous peripheral blood stem cells (PBSC) were harvested after five courses of chemotherapy. Bone Marrow Transplantation prednisolone (10 mg) on day 1. From 2 days after the end of chemotherapy to the last day of harvest, stem cells were mobilized with s.c. 5 g/kg rhG-CSF (Neupogen; Amgen, Munich, Germany). At the time of apheresis the patient weighed 40 kg. PBSC I, II, III was collected on days 9, 10 and 11 of mobilization using a Cobe Spectra (Cobe Laboratories, Lakewood, CO, USA).
CD133
+ selection CD133 + cells were immunomagnetically selected from aphereses using the automated CliniMacs system (Miltenyi/Biotec, Bergisch-Gladbach, Germany). Cells were processed as described for CD34 selection 4, 6 under GMP conditions. Briefly, both the pooled PBSC I+II and PBSC III in a separated run were washed twice with CliniMacs PBS/EDTA buffer (Miltenyi/Biotec) supplemented with 0.4% human serum albumine (BSD Hessia, Frankfurt, Germany) for platelet reduction and cells were resuspended to a total volume of 80 ml. To avoid nonspecific binding, cells were incubated with 5 ml intraglobine (50 g/ml; Biotest, Frankfurt, Germany) for 5 min. Cells were then labeled with anti-CD133 antibodies (CD133 + microbeads, kindly provided by Miltenyi/Biotec) for 30 min at 4°C. After incubation, cells were washed twice with CliniMacs PBS/EDTA buffer by centrifugation at 1100 g for 15 min. Finally, CD133 positive selection was performed using the software programme 'enrichment 2.1' on the CliniMacs system.
Conditioning regimen and ASCR
The patient received TBI on days Ϫ7, to Ϫ4 (12 Gy total body, 18 Gy cranial) and etoposide on day Ϫ3 (60 mg/kg). Seventy-two hours after the completion of the radio-chemotherapy, cryopreserved stem cells were thawed rapidly and a total of 2.5 ϫ 10 6 CD133 + /CD34 + cells/kg were reinfused.
Flow cytometric analysis
Three-and four-color flow cytometric analyses were performed on a Coulter Epics XL (Coulter, Krefeld, Germany) to determine the percentage of leukocytes expressing CD133 + and CD34 + in PBSC and CD133 + selected preparations. Moreover, we searched for residual leukemic blasts. After transplantation, we monitored the reconstitution of immunological subtypes in the peripheral blood. Briefly, 2 ϫ 10 5 -1 ϫ 10 6 cells were labeled for 20 min in separate tubes with CD34-FITC/CD133-PE/CD45-PC5 for determination of progenitor cells. Also, CD45FITC/CD34PE/7-AAD including stem-count beads (Stem-Kit/Coulter Immunotech and 7-AAD) was used to evaluate the absolute count of CD34
+ cells according to a modified ISHAGE protocol. For detection of residual leukemic cells prior to and after CD133 selection, cells were labeled with CD19-FITC/CD10-PE/CD45-ECD/CD34-PC5, CD19-FITC/CD133-PE/CD45-ECD/CD34-PC5 as well as CD19-FITC/CD34-PE/PI. Immune reconstitution was monitored in T cell subsets, NK cells and B cells in weekly peripheral blood samples during the first 100 days post transplant, then monthly samples or according to the current patient status. For this, cells were FITC/PE/ECD/PC5-labeled with CD45/CD4/CD8/CD3, CD45/CD56/CD19/CD3, HLA-DR/CD38/CD3/CD8, HLA-DR/CD38/CD3/CD4, CD45RA/CD45RO/CD3/CD4, CD45RA/CD45RO/CD3/CD8 and CD4/CD69/CD3/CD8. CD133-1-PE and CD133-2-PE were obtained from Miltenyi/Biotec; all other antibodies were from Coulter Immunotech (Marseille, France). Dead cells were detected and excluded from analysis by 7-AAD and propidiumiodide (PI) staining. Additionally, IgG1-FITC/IgG1-PE/IgG1-ECD/IgG1-PC5 and IgG1-FITC/IgG1-PE/CD45-ECD/IgG1-PC5 staining served as controls.
Results
Collection and positive selection of CD133
+ cells
Three leukaphereses were performed. Viability of the cells was Ͼ97% prior to and after purification. Recovery of CD133
+ hematopoietic progenitor cells resulted in 63.9 Ϯ 5.5% while the recovery of CD34
+ cells was 48.1 Ϯ 4.2%, respectively ( Table 1) .
Detection of residual leukemic cells
Due to nonspecific staining of membrane particles, which cannot be excluded from analysis by 7-AAD or propidiumiodide, flow cytometric analysis did not allow for definitive exclusion of residual leukemic blasts (CD45 + CD34 + CD19 + CD10 + ) in apheresis products I, II, III and one selected graft (in both cases, Ͻ0.02%). The second purified graft stained negatively. Molecular genetic screening for blasts was not possible, since the leukemic blasts were negative for the fusion transcripts TEL-AML1, BCR-ABL and MLL-1 determined by PCR. + /kg) were taken from PBSC I for cryoconservation of an unselected back up product. The final half part of PBSC I (9/20 of PBSC I) was pooled with PBSC II and selected by CD133 enrichment. PBSC III was purified in an independent run. b Recovery for CD133 + and CD34 + cells was determined dividing the absolute count of the respective cells after selection by that before selection. 
Hematopoietic recovery
Engraftment was seen on days 13, 13 and 24 for leukocytes (Ͼ1.0 ϫ 10 9 /l), neutrophils (Ͼ1.0 ϫ 10 9 /l), and platelets (Ͼ50.0 ϫ 10 9 /l), respectively. This is comparable with the engraftment after reinfusion of CD34 + selected cells as shown for the absolute number of neutrophils count (ANC) of some of our pediatric patients (four neuroblastoma, one Ewing's sarcoma, one osteosarcoma, one rhabdomyosarcoma; Figure 2 ). These patients were transplanted with a similar dose of autologous CD34 + stem cells (1.8-4.0 ϫ 10 6 /kg). Generally, to accelerate recovery, all our patients 
Bone Marrow Transplantation
were treated with rhG-CSF for 14-15 days after autologous transplantation.
Monitoring of different immunological subtypes is illustrated in Figure 3 . CD19 + B cell recovery started as early as 1.5 months Figure 3 ). No striking difference to other patients was observed in the activation markers on the various T cell subsets.
Clinical status after transplantation
Infusion of CD133 selected progenitor cells was well tolerated. The patient did not show any allergical reactions or side-effects due to the remaining CD133 microbeads on the surface of the progenitor cells. No viral or fungal infection or other kind of complication during and after hematopoietic recovery was seen. No additional late toxicities have been observed. With a follow-up of 11 1 2 months after transplantation, the boy is alive with a good performance status in continuous complete remission. 
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Discussion
Very early leukemic relapse in the CNS continues to be a difficult therapeutic challenge. Intensification of chemotherapy prior to allogeneic transplantation did not improve prognosis. Because a few cases are reported with similar or better outcome after autologous transplantation, high-dose chemotherapy with reinfusion of autografts seems to be an alternative worth exploring for these patients. 1 For autologous grafts, a refined selection technique is indispensable to yield a high purity of progenitor cells and to avoid a relapse due to residual leukemic contamination. For pediatric patients with neuroblastoma, Brenner et al 2 showed direct evidence that neuroblastoma cells present in patients' bone marrow or peripheral blood stem cell grafts can contribute to relapse. The commonly used CD34 selection is an excellent technique to achieve a high purity of CD34 cells. 7 In various trials, clinical scale CD34 selection led to a median purity of 96-97% CD34 + cells. 4, 6, 7 However, the use of a CD34 enrichment technique is not to be recommended in cases of CD34 positive malignancies. Rather, enrichment with the new progenitor antigen CD133 may present a preferable purification strategy in selected cases. Several studies demonstrated that the majority of ALLs are double positive for CD133 and CD34. 8, 9 Therefore, purification with CD133 can be used for a minority of ALLs, only.
In our previous work, we compared large scale CD34 and CD133 purification of autologous grafts of pediatric patients with neuroblastoma. 4 Both selection strategies led to similar high median purities of 98.0% and 97.3% CD34 + cells. No contaminating neuroblastoma cells remained as determined by RT-PCR for tyrosine hydroxylase. These patients were transplanted with CD34 selected progenitor cells, only. Experimentally data demonstrate a higher proliferating and self-replicating capacity of CD133 + CD34 + cells in comparison to CD133 Ϫ CD34 + cells. The latter contain committed progenitors, which do not have full reconstituting capacity. 5, [10] [11] [12] An extremely rare population of cells lacking CD34 and lineage commitment markers (CD34 Ϫ lin Ϫ CD38 Ϫ ) is positive for CD133 and shows a very high reconstituting ability. 12 This gives rise to the thought that CD133 selected cells might be superior for stem cell transplantation to CD34 selected cells. We saw that CD133 selection led to enrichment of this rare CD133 + CD34 Ϫ progenitor cell population together with the CD133 + CD34 + double positive cells. Therefore, fewer progenitor cells in the graft might be sufficient to reach full reconstitution. However, hematopoietic recovery of our patient reported here did not differ significantly from that of our patients receiving the same number of conventionally selected stem cells. Additionally, reconstitution of the immunological subsets did not show remarkable differences to patients treated with CD34-enriched grafts. To date, the literature lacks any data about transplantation with CD133 enriched progenitors. Therefore, to our knowledge, the successful transplantation with a CD133 selected graft of our patient with a CD34 + CD133 Ϫ ALL is the first one to be reported worldwide.
In summary, large scale CD133 positive selection is feasible and achieves equivalent high purities of progenitor cells equivalent to that previously reported for CD34 selection. Tumor and leukemic cell depletion is effective with this method. CD133 selected grafts can lead to full hematopoietic reconstitution. Therefore, CD133 purification presents a favorable alternative to CD34 selection of autologous grafts in patients with CD34-positive but CD133-negative malignant cells.
